What is the next earnings date for CARA stock?
CARA THERAPEUTICS INC (CARA) will report earnings on 2025-05-12, after the market close.
CARA THERAPEUTICS INC (CARA) Forecast, Price Target & Analyst Ratings
NASDAQ:CARA • US1407552082
Current stock price
5.32 USD
-0.23 (-4.14%)
At close:
5.43 USD
+0.11 (+2.07%)
After Hours:
Analyst forecast overview
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for CARA THERAPEUTICS INC (CARA).
Forecast Snapshot
Next Earnings Forecast
Earnings Estimate- Release Date
- May 12, 2025
- Period
- Q1 / 2025
- EPS Estimate
- -$0.20
- Revenue Estimate
- 1.224M
Price Target Details & History
Consensus Price Target and Range
Mean target
N/A
Upside
N/A
From current price of $5.32 to mean target of N/A, Based on 6 analyst forecasts
Low
N/A
Median
N/A
High
N/A
Price Target Revisions
1 Month
0.00%
3 Months
1,100.00%
Price Target Summary
The average price target has been revised upward by 1100% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
43.33%
CARA was analyzed by 6 analysts. The buy percentage consensus is at 43. So analysts seem to be rather negative about CARA.
In the previous month the buy percentage consensus was at a similar level.
CARA was analyzed by 6 analysts. More opinions would make the average more meaningful.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2024-06-13 | Needham | Downgrade | Buy -> Hold |
| 2024-06-13 | Canaccord Genuity | Downgrade | Buy -> Hold |
| 2024-06-13 | HC Wainwright & Co. | Downgrade | Buy -> Neutral |
| 2024-05-23 | Needham | Reiterate | Buy -> Buy |
| 2024-05-15 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-05-14 | Needham | Reiterate | Buy -> Buy |
| 2024-04-10 | Needham | Reiterate | Buy -> Buy |
| 2024-03-28 | Needham | Reiterate | Buy -> Buy |
| 2024-03-06 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2024-03-05 | Needham | Reiterate | Buy -> Buy |
| 2024-01-22 | Needham | Maintains | Buy -> Buy |
| 2023-12-19 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2023-12-18 | Needham | Maintains | Buy -> Buy |
| 2023-11-14 | Piper Sandler | Downgrade | Overweight -> Neutral |
| 2023-10-19 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2023-08-08 | Needham | Reiterate | Buy -> Buy |
| 2023-08-08 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2023-06-27 | Stifel | Reiterate | Buy -> Buy |
| 2023-06-27 | Jefferies | Reiterate | Buy -> Buy |
| 2023-05-16 | Needham | Reiterate | Buy |
| 2023-05-16 | B of A Securities | Maintains | Underperform -> Underperform |
| 2023-05-16 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2023-04-18 | Needham | Reiterate | Action List Buy |
| 2023-04-04 | Needham | Reiterate | Buy |
| 2023-03-08 | B of A Securities | Downgrade | Neutral -> Underperform |
Next Earnings Forecast Details
Next Earnings Details
- Release Date
- May 12, 2025
- Period
- Q1 / 2025
- EPS Estimate
- -$0.20
- Revenue Estimate
- 1.224M
- Revenue Q2Q
- -42.67%
- EPS Q2Q
- 96.96%
- Number of Analysts
- 3
Next Earnings Revisions
Revenue (1 Month)
0.00%
Revenue (3 Months)
0.00%
EPS (1 Month)
0.00%
EPS (3 Months)
0.00%
Next Earnings Summary
CARA is expected to report earnings on 5/12/2025. The consensus EPS estimate for the next earnings is -0.2 USD and the consensus revenue estimate is 1.22M USD.
The next earnings revenue estimate has been revised downward by 0% in the past 3 months.
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 41.9M 82.17% | 20.968M -49.96% | 7.137M -65.96% | 3.672M -48.55% | 1.53M -58.33% | 19.327M 1,163.20% | 51.768M 167.85% | 65.919M 27.34% | 39.101M -40.68% | 334.14M 754.56% | |
| EBITDA YoY % growth | -87.25M 1.80% | -121.236M -38.95% | -52.626M 56.59% | -66.289M -25.96% | -64.714M 2.38% | -57.964M 10.43% | -56.107M 3.20% | -61.364M -9.37% | -53.786M 12.35% | 183.91M 441.93% | |
| EBIT YoY % growth | -87.5M 1.80% | -121.495M -38.85% | -52.818M 56.53% | -75.684M -43.29% | -60.588M 19.95% | -50.912M 15.97% | -32.287M 36.58% | -26.092M 19.19% | -53.786M -106.14% | 164.75M 406.31% | |
| Operating Margin | -208.83% | -579.43% | -740.06% | -2,061.11% | -3,960.00% | -263.42% | -62.37% | -39.58% | -137.56% | 49.31% | |
| EPS YoY % growth | -1.59 8.09% | -2.18 -37.11% | N/A 39.95% | -0.79 40.00% | -0.65 17.75% | -0.73 -12.90% | -0.61 16.78% | -0.37 39.50% | -0.73 -100.00% | 1.80 344.44% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q1 / 25 | Q2 / 25 | Q3 / 25 | Q4 / 25 | |
|---|---|---|---|---|
| EPS Q2Q % growth | -0.20 96.96% | -0.21 95.18% | -0.23 91.50% | -0.20 -5.26% |
| Revenue Q2Q % growth | 1.224M -42.67% | 1.02M 2.93% | 816K -68.08% | 612K -57.94% |
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -16.83M 38.27% | -17.952M -21.92% | -19.482M -268.91% | -21.42M -286.15% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
13.00%
EPS Next 5 Year
11.45%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
58.04%
Revenue Next 5 Year
68.20%
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
10.58%
EBIT Next 5 Year
5.61%
CARA THERAPEUTICS INC / CARA Forecast FAQ
What are the consensus estimates for CARA stock next earnings?
The consensus EPS estimate for the next earnings of CARA THERAPEUTICS INC (CARA) is -0.2 USD and the consensus revenue estimate is 1.22M USD.
What is the expected long term growth rate for CARA THERAPEUTICS INC (CARA)?
The expected long term growth rate for CARA THERAPEUTICS INC (CARA) is 58.04%.